Show Summary Details
Page of

Primary Liver Tumors 

Primary Liver Tumors
Primary Liver Tumors

Samuel L. Rice

, Stephen B. Solomon

, and David C. Madoff

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 03 August 2020

Primary liver tumors result in substantial morbidity and mortality. Unfortunately, the majority of these tumors are discovered when the disease has progressed beyond the possibility of a curative surgical intervention. Over the past few decades, minimally invasive transcatheter and percutaneous techniques have been developed that offer patients with primary liver tumors extended survival, improved quality of life, and even potentially curative treatment. These therapies comprise procedures that embolize and locally deliver chemotherapy or radioactivity to these tumors or apply thermal or nonthermal ablative techniques that can be performed via a percutaneous approach utilizing computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) to kill tumor cells directly, with achievement of an appropriative therapeutic margin. This chapter focuses on the workup and clinical management of patients with primary liver cancer; hepatocellular carcinoma (HCC), and cholangiocarcinoma, as well as the role that these aforementioned interventional oncologic techniques have in treating these neoplasms.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.